Welcome to Psychedelic Alpha

Welcome to Psychedelic Alpha.

Thank you for joining our free newsletter, I'm glad to have you here. (If you subscribed to our paid plan, Pα+ , you should have already received a separate welcome email.)

Psychedelic Alpha is an independent media, research, and advisory organisation focused on the development, regulation, and delivery of psychedelic medicines. Founded in 2020 by me, Josh Hardman, we are known for rigorous, data-driven coverage of drug development, policy, and access.

Via this free list, we will send you a weekly digest of the Psychedelic News Feed, plus the occasional article. If you’re after more in-depth content, please consider subscribing to our Pα+ plan (more on that below).

You might enjoy exploring these resources to get you started:

• 📰 our Psychedelic News Feed shares the latest coverage;

• 🎥 our latest Quarterly Briefing gets you up to speed;

• 💊 our Psychedelics Drug Development Tracker and Bullseye Chart tracks drug discovery and development;

• 💼 our Psychedelic Job Board collects the latest opportunities;

• 🗃️ you can browse our back catalogue, too.

Want to go deeper? Many of our readers upgrade to our paid plan for the full picture.

Subscribe to Pα+ for Exclusive Insights

Pα+ subscribers receive regular Bulletins, in-depth articles, insider interviews, and quick-take analysis of major developments — from trial results to policy reforms. You'll also get quarterly video briefings and much more. If you haven’t already, learn more here, or click the buttons below to subscribe today:

Interested in a group or corporate plan? Simply reply to this email to get started.

What Are You Interested In?

What interests you about the emergent psychedelics space, or Psychedelic Alpha in particular? Please do let me know by replying to this email (I reply to every email).

That's all for now - thanks again for joining our community.

Best wishes,

Josh Hardman

Founder, Editor